References

therapeutic

Южно-Российский журнал терапевтической практики

South Russian Journal of Therapeutic Practice

2712-81563033-8344

РостГМУ

10.21886/2712-8156-2021-2-4-22-29

therapeutic-178

Research Article

ОБЗОРЫ

REVIEWS

Хроническая обструктивная болезнь легких и фибрилляция предсердий

Chronic obstructive pulmonary disease and atrial fibrillation

https://orcid.org/0000-0003-2660-901X

Глова

С. Е.

Glova

S. E.

Глова Светлана Евгеньевна, кандидат медицинских наук, доцент кафедры терапии

Ростов-на-Дону

Svetlana E. Glova, Cand. Sci. (Med.), Associate Professor, Chair of Therapy

Rostov-on-Don

glova_svetlana@mail.ru

https://orcid.org/0000-0001-7747-7796

Разумовский

И. В.

Razumovsky

I. V.

Разумовский Игорь Валерьевич, аспирант кафедры терапии кафедры терапии

Ростов-на-Дону

Igor V. Razumovsy, postgraduate, Chair of Therapy

Rostov-on-Don

igorrazumovsky@mail.ru

ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава РоссииРоссияRostov State Medical UniversityRussian Federation

2021

27112021

242229

2021

Глова С.Е., Разумовский И.В.

Glova S.E., Razumovsky I.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.therapeutic-j.ru/jour/article/view/178

Хроническая обструктивная болезнь лёгких (ХОБЛ) имеет тесную взаимосвязь с развитием сердечной недостаточности и фибрилляции предсердий (ФП). В патогенезе развития ФП у пациентов с ХОБЛ имеют значение снижение оксигенации, гиперкапния, лёгочная гипертензия, диастолическая дисфункция, окислительный стресс, воспаление, изменения размера предсердий, а также использование респираторных препаратов для лечения ХОБЛ. Понимание взаимосвязи между ХОБЛ и ФП имеет особое значение, поскольку наличие аритмии оказывает значительное влияние на смертность, особенно при обострениях ХОБЛ. При наличии ХОБЛ у пациентов с ФП наблюдается более быстрое прогрессированием ФП, рецидивы ФП после катетерной аблации, а также увеличением смертности от сердечно‑сосудистых заболеваний. Лечение основного заболевания, коррекция гипоксии и кислотно‑щелочного дисбаланса является терапией первой линии для пациентов с ХОБЛ, у которых развивается ФП. Кардиоселективные β‑адреноблокаторы безопасны и могут применяться при ХОБЛ. Аблация при ФП является эффективной и безопасной, а также улучшает качество жизни этих пациентов.

Chronic obstructive pulmonary disease (COPD) has a close relationship with the development of heart failure and atrial fibrillation (AF). In the pathogenesis of AF in patients with COPD, decreased oxygenation, hypercapnia, pulmonary hypertension, diastolic dysfunction, oxidative stress, inflammation, changes in atrial size, and the use of respiratory drugs for the treatment of COPD are important. Understanding the relationship between COPD and AF is of particular importance because the presence of arrhythmias has a significant impact on mortality, especially in exacerbations of COPD. In the presence of COPD, patients with AF have a more rapid progression of AF, recurrence of AF after catheter ablation, and an increase in mortality from cardiovascular diseases. Treatment of the underlying disease, correction of hypoxia and acid‑base imbalance is the first line therapy for patients with COPD who develop AF. Cardioselective β‑blockers are safe and can be used for COPD. AF ablation is effective and safe and improves the quality of life of these patients.

хроническая обструктивная болезнь легкихфибрилляция предсердийпатофизиологические механизмы развитиялечениепрогнозобзор

chronic obstructive pulmonary diseaseatrial fibrillationpathophysiological mechanisms of developmenttreatmentprognosisreview

References1

Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187 (4):347–65. DOI: 10.1164/rccm.201204–0596PP.

Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013 Feb 15;187(4):347-65. doi: 10.1164/rccm.201204-0596PP. Epub 2012 Aug 9. PMID: 22878278.

Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015;5 (2):020415. DOI: 10.7189/jogh.05–020415.

Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, Nair H, Gasevic D, Sridhar D, Campbell H, Chan KY, Sheikh A, Rudan I; Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015 Dec;5(2):020415. doi: 10.7189/jogh.05-020415. PMID: 26755942; PMCID: PMC4693508.

Beyerbach DM, Zipes DP. Mortality as an endpoint in atrial fibrillation. Heart Rhythm. 2004;1 (2 Suppl): B8–18, discussion B18–9. DOI: 10.1016/j.hrthm.2004.04.018.

Beyerbach DM, Zipes DP. Mortality as an endpoint in atrial fibrillation. Heart Rhythm. 2004 Jul;1(2 Suppl):B8-18, discussion B18-9. doi: 10.1016/j.hrthm.2004.04.018. PMID: 15851134.

Chahal H, Heckbert SR, Barr RG, Bluemke DA, Jain A, Habibi M, et al. Ability of Reduced Lung Function to Predict Development of Atrial Fibrillation in Persons Aged 45 to 84 Years (from the Multi-Ethnic Study of Atherosclerosis-Lung Study). Am J Cardiol. 2015;115 (12):1700–4. DOI: 10.1016/j.Amjcard.2015.03.018.

Chahal H, Heckbert SR, Barr RG, Bluemke DA, Jain A, Habibi M, Alonso A, Kronmal R, Jacobs DR Jr, Lima JA, Watson KE, Liu K, Smith LJ, Greenland P. Ability of Reduced Lung Function to Predict Development of Atrial Fibrillation in Persons Aged 45 to 84 Years (from the Multi-Ethnic Study of Atherosclerosis-Lung Study). Am J Cardiol. 2015 Jun 15;115(12):1700-4. doi: 10.1016/j.amjcard.2015.03.018. Epub 2015 Mar 24. PMID: 25900353; PMCID: PMC4450133.

Konecny T, Park JY, Somers KR, Konecny D, Orban M, Soucek F, et al. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am J Cardiol. 2014;114 (2):272–7. DOI: 10.1016/j.amjcard.2014.04.030.

Konecny T, Park JY, Somers KR, Konecny D, Orban M, Soucek F, Parker KO, Scanlon PD, Asirvatham SJ, Brady PA, Rihal CS. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am J Cardiol. 2014 Jul 15;114(2):272-7. doi: 10.1016/j.amjcard.2014.04.030. Epub 2014 May 2. PMID: 24878126.

Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J. 2003;21 (6):1012–6. DOI: 10.1183/09031936.03.00051502.

Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J. 2003 Jun;21(6):1012-6. doi: 10.1183/09031936.03.00051502. PMID: 12797497.

Li J, Agarwal SK, Alonso A, Blecker S, Chamberlain AM, London SJ, et al. Airflow obstruction, lung function, and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2014;129 (9):971–80. DOI: 10.1161/CIRCULATIONAHA.113.004050.

Li J, Agarwal SK, Alonso A, Blecker S, Chamberlain AM, London SJ, Loehr LR, McNeill AM, Poole C, Soliman EZ, Heiss G. Airflow obstruction, lung function, and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2014 Mar 4;129(9):971-80. doi: 10.1161/CIRCULATIONAHA.113.004050. Epub 2013 Dec 16. PMID: 24344084; PMCID: PMC3963836.

Johnson LS, Juhlin T, Engström G, Nilsson PM. Reduced forced expiratory volume is associated with increased incidence of atrial fibrillation: the Malmo Preventive Project. Europace. 2014;16 (2):182–8. DOI: 10.1093/europace/eut255.

Geçmen Ç, Babür Güler G, Erdoğan E, Hatipoğlu S, Güler E, Yılmaz F, et al. SYNTAX score predicts postoperative atrial fibrillation in patients undergoing on-pump isolated coronary Artery bypass grafting surgery. Anatol J Cardiol. 2016;16 (9):655–61. DOI: 10.5152/anatoljcardiol.2015.6483.

Geçmen Ç, Babür Güler G, Erdoğan E, Hatipoğlu S, Güler E, Yılmaz F, Unkun T, Cap M, Bengi Bakal R, Bayram T, Deniz Acar R, Candan Ö, Özdemir N. SYNTAX score predicts postoperative atrial fibrillation in patients undergoing on-pump isolated coronary artery bypass grafting surgery. Anatol J Cardiol. 2016 Sep;16(9):655-61. doi: 10.5152/AnatolJCardiol.2015.6483. Epub 2015 Nov 18. PMID: 27488747; PMCID: PMC5331348.

Terzano C, Romani S, Conti V, Paone G, Oriolo F, Vitarelli A. Atrial fibrillation in the acute, hypercapnic exacerbations of COPD. Eur Rev Med Pharmacol Sci. 2014;18 (19):2908–17. PMID: 25339486.

Terzano C, Romani S, Conti V, Paone G, Oriolo F, Vitarelli A. Atrial fibrillation in the acute, hypercapnic exacerbations of COPD. Eur Rev Med Pharmacol Sci. 2014 Oct;18(19):2908-17. PMID: 25339486.

Krause PC, Inoue H, Zipes DP. Electrophysiologic alterations produced by hypoxia in the canine heart. Am Heart J. 1989;117 (3):550–61. DOI: 10.1016/0002–8703 (89)90728-x.

Krause PC, Inoue H, Zipes DP. Electrophysiologic alterations produced by hypoxia in the canine heart. Am Heart J. 1989 Mar;117(3):550-61. doi: 10.1016/0002-8703(89)90728-x. PMID: 2493188.

Stevenson IH, Roberts-Thomson KC, Kistler PM, Edwards GA, Spence S, Sanders P, et al. Atrial electrophysiology is altered by acute hypercapnia but not hypoxemia: implications for promotion of atrial fibrillation in pulmonary disease and sleep apnea. Heart Rhythm. 2010;7 (9):1263–70. DOI: 10.1016/j.Hrthm.2010.03.020.

Stevenson IH, Roberts-Thomson KC, Kistler PM, Edwards GA, Spence S, Sanders P, Kalman JM. Atrial electrophysiology is altered by acute hypercapnia but not hypoxemia: implications for promotion of atrial fibrillation in pulmonary disease and sleep apnea. Heart Rhythm. 2010 Sep;7(9):1263-70. doi: 10.1016/j.hrthm.2010.03.020. Epub 2010 Mar 22. PMID: 20338265.

Ogi H, Nakano Y, Niida S, Dote K, Hirai Y, Suenari K, et al. Is structural remodeling of fibrillated atria the consequence of tissue hypoxia? Circ J. 2010;74 (9):1815–21. DOI: 10.1253/circj.Cj-09–0969.

Ogi H, Nakano Y, Niida S, Dote K, Hirai Y, Suenari K, Tonouchi Y, Oda N, Makita Y, Ueda S, Kajihara K, Imai K, Sueda T, Chayama K, Kihara Y. Is structural remodeling of fibrillated atria the consequence of tissue hypoxia? Circ J. 2010 Sep;74(9):1815-21. doi: 10.1253/circj.cj-09-0969. Epub 2010 Jul 10. PMID: 20631454.

Su F, Zhang W, Chen Y, Ma L, Zhang H, Wang F. Significance of hypoxia-inducible factor-1α expression with atrial fibrosis in rats induced with isoproterenol. Exp Ther Med. 2014;8 (6):1677–1682. DOI: 10.3892/etm.2014.1989.

Su F, Zhang W, Chen Y, Ma L, Zhang H, Wang F. Significance of hypoxia-inducible factor-1α expression with atrial fibrosis in rats induced with isoproterenol. Exp Ther Med. 2014 Dec;8(6):1677-1682. doi: 10.3892/etm.2014.1989. Epub 2014 Sep 24. PMID: 25371714; PMCID: PMC4218706.

Sievi NA, Clarenbach CF, Camen G, Rossi VA, van Gestel AJ, Kohler M. High prevalence of altered cardiac repolarization in patients with COPD. BMC Pulm Med. 2014;14:55. DOI: 10.1186/1471–2466–14–55.

Sievi NA, Clarenbach CF, Camen G, Rossi VA, van Gestel AJ, Kohler M. High prevalence of altered cardiac repolarization in patients with COPD. BMC Pulm Med. 2014 Apr 2;14:55. doi: 10.1186/1471-2466-14-55. PMID: 24690123; PMCID: PMC3976227.

Mandyam MC, Soliman EZ, Alonso A, Dewland TA, Heckbert SR, Vittinghoff E, et al. The QT interval and risk of incident atrial fibrillation. Heart Rhythm. 2013;10 (10):1562–8. DOI: 10.1016/j.hrthm.2013.07.023.

Mandyam MC, Soliman EZ, Alonso A, Dewland TA, Heckbert SR, Vittinghoff E, Cummings SR, Ellinor PT, Chaitman BR, Stocke K, Applegate WB, Arking DE, Butler J, Loehr LR, Magnani JW, Murphy RA, Satterfield S, Newman AB, Marcus GM. The QT interval and risk of incident atrial fibrillation. Heart Rhythm. 2013 Oct;10(10):1562-8. doi: 10.1016/j.hrthm.2013.07.023. Epub 2013 Jul 18. PMID: 23872693; PMCID: PMC3787974.

Nguyen KT, Gladstone RA, Dukes JW, Nazer B, Vittinghoff E, Badhwar N, et al. The QT Interval as a Noninvasive Marker of Atrial Refractoriness. Pacing Clin Electrophysiol. 2016;39 (12):1366–1372. DOI: 10.1111/pace.12962.

Nguyen KT, Gladstone RA, Dukes JW, Nazer B, Vittinghoff E, Badhwar N, Vedantham V, Gerstenfeld EP, Lee BK, Lee RJ, Tseng ZH, Olgin JE, Scheinman MM, Marcus GM. The QT Interval as a Noninvasive Marker of Atrial Refractoriness. Pacing Clin Electrophysiol. 2016 Dec;39(12):1366-1372. doi: 10.1111/pace.12962. Epub 2016 Nov 10. PMID: 27753113; PMCID: PMC5195901.

Acar G, Kahraman H, Akkoyun M, Kilinc M, Zencir C, Yusufoglu E, et al. Evaluation of atrial electromechanical delay and its relationship to inflammation and oxidative stress in patients with chronic obstructive pulmonary disease. Echocardiography. 2014;31 (5):579–85. DOI: 10.1111/echo.2442.

Acar G, Kahraman H, Akkoyun M, Kilinc M, Zencir C, Yusufoglu E, Dirnak I, Sahin H, Olmez S, Akcay A, Ardic I. Evaluation of atrial electromechanical delay and its relationship to inflammation and oxidative stress in patients with chronic obstructive pulmonary disease. Echocardiography. 2014 May;31(5):579-85. doi: 10.1111/echo.12442. Epub 2013 Dec 24. PMID: 24372655.

Bhatt SP, Nanda S, Kintzer JS. Arrhythmias as trigger for acute exacerbations of chronic obstructive pulmonary disease. Respir Med. 2012;106 (8):1134–8. DOI: 10.1016/j.Rmed.2012.04.007.

Bhatt SP, Nanda S, Kintzer JS. Arrhythmias as trigger for acute exacerbations of chronic obstructive pulmonary disease. Respir Med. 2012 Aug;106(8):1134-8. doi: 10.1016/j.rmed.2012.04.007. Epub 2012 May 16. PMID: 22595809.

Bhatt SP, Nanda S, Kintzer JS. Arrhythmias as trigger for acute exacerbations of chronic obstructive pulmonary disease. Respir Med. 2012;106 (8):1134–8. DOI: 10.1016/j. Rmed.2012.04.007.

Hayashi H, Miyamoto A, Kawaguchi T, Naiki N, Xue JQ, Matsumoto T, et al. P-pulmonale and the development of atrial fibrillation. Circ J. 2014;78 (2):329–37. DOI: 10.1253/circj.Cj-13–0654.

Hayashi H, Miyamoto A, Kawaguchi T, Naiki N, Xue JQ, Matsumoto T, Murakami Y, Horie M. P-pulmonale and the development of atrial fibrillation. Circ J. 2014;78(2):329-37. doi: 10.1253/circj.cj-13-0654. Epub 2013 Nov 27. PMID: 24284921.

Baum C, Ojeda FM, Wild PS, Rzayeva N, Zeller T, Sinning CR, et al. Subclinical impairment of lung function is related to mild cardiac dysfunction and manifest heart failure in the general population. Int J Cardiol. 2016;218:298–304. DOI: 10.1016/j.Ijcard.2016.05.034.

Baum C, Ojeda FM, Wild PS, Rzayeva N, Zeller T, Sinning CR, Pfeiffer N, Beutel M, Blettner M, Lackner KJ, Blankenberg S, Münzel T, Rabe KF, Schnabel RB; Gutenberg Health Study investigators. Subclinical impairment of lung function is related to mild cardiac dysfunction and manifest heart failure in the general population. Int J Cardiol. 2016 Sep 1;218:298-304. doi: 10.1016/j.ijcard.2016.05.034. Epub 2016 May 14. PMID: 27240155.

Agoston-Coldea L, Petrovai D, Mihalcea I, Revnic R, Mocan T, Lupu S. Right Atrium Volume Index in Patients with Secondary Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease. Acta Cardiol Sin. 2015;31 (4):325–36. DOI: 10.6515/acs20150119a.

Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J. 2015;79 (3):495–502. DOI: 10.1253/circj.CJ-15–0138.

Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J. 2015;79(3):495-502. doi: 10.1253/circj.CJ-15-0138. Epub 2015 Feb 16. PMID: 25746525; PMCID: PMC4457364.

Wilcheskym,ernstp,brophyjm,plattrw,Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest. 2012;142 (2):305–311. DOI: 10.1378/chest.11–1597.

Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest. 2012 Aug;142(2):305-311. doi: 10.1378/chest.11-1597. PMID: 22871756.

Kallergis EM, Manios EG, Kanoupakis EM, Schiza SE, Mavrakis HE, Klapsinos NK, et al. Acute electrophysiologic effects of inhaled salbutamol in humans. Chest. 2005;127 (6):2057–63. DOI: 10.1378/chest.127.6.2057.

Kallergis EM, Manios EG, Kanoupakis EM, Schiza SE, Mavrakis HE, Klapsinos NK, Vardas PE. Acute electrophysiologic effects of inhaled salbutamol in humans. Chest. 2005 Jun;127(6):2057-63. doi: 10.1378/chest.127.6.2057. PMID: 15947320.

Singh S, Loke YK, Enright P, Furberg CD. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax. 2013;68 (1):114–6. DOI: 10.1136/thoraxjnl-2011-201275.

Singh S, Loke YK, Enright P, Furberg CD. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax. 2013 Jan;68(1):114-6. doi: 10.1136/thoraxjnl-2011-201275. Epub 2012 Jul 4. PMID: 22764216.

Anthonisen NR, Connett JE, Enright PL, Manfreda J; Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002;166 (3):333–9. DOI: 10.1164/rccm.2110093.

Anthonisen NR, Connett JE, Enright PL, Manfreda J; Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002 Aug 1;166(3):333-9. doi: 10.1164/rccm.2110093. PMID: 12153966.

Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD. Cardiovascular events associated with ipratropium bromide in COPD. Chest. 2010;137 (1):13–9. DOI: 10.1378/chest.08–2367.

Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD. Cardiovascular events associated with ipratropium bromide in COPD. Chest. 2010 Jan;137(1):13-9. doi: 10.1378/chest.08-2367. Epub 2009 Apr 10. PMID: 19363211.

Hohlfeld JM, Furtwaengler A, Könen-Bergmann M, Wallenstein G, Walter B, Bateman ED. Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials. Int J Clin Pract. 2015;69 (1):72–80. DOI: 10.1111/ijcp.12596.

Huerta C, Lanes SF, García Rodríguez LA. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology. 2005;16 (3):360–6. DOI: 10.1097/01.ede.0000158743.90664.a7.

Huerta C, Lanes SF, García Rodríguez LA. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology. 2005 May;16(3):360-6. doi: 10.1097/01.ede.0000158743.90664.a7. PMID: 15824553.

Christiansen CF, Christensen S, Mehnert F, Cummings SR, Chapurlat RD, Sørensen HT. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, casecontrol study. Arch Intern Med. 2009;169 (18):1677–83. DOI: 10.1001/archinternmed.2009.297.

Christiansen CF, Christensen S, Mehnert F, Cummings SR, Chapurlat RD, Sørensen HT. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Arch Intern Med. 2009 Oct 12;169(18):1677-83. doi: 10.1001/archinternmed.2009.297. PMID: 19822824.

Grabicki M, Parysek H, Batura-Gabryel H, Brodnicka I. Comorbidities as an element of multidimensional prognostic assessment of patients with chronic obstructive pulmonary disease. J Physiol Pharmacol. 2008;59 Suppl 6:297–301. PMID: 19218653.

Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive Pulmonary disease. Thorax. 2012;67 (11):970–6. DOI: 10.1136/thoraxjnl-2012–202103.

Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax. 2012 Nov;67(11):970-6. doi: 10.1136/thoraxjnl-2012-202103. Epub 2012 Aug 15. PMID: 22895999.

De Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol. 2010;55 (8):725–31. DOI: 10.1016/j.jacc.2009.11.040.

de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ, van den Heijkant AC, Allessie MA, Crijns HJ. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol. 2010 Feb 23;55(8):725-31. doi: 10.1016/j.jacc.2009.11.040. PMID: 20170808.

Emren SV, Kocabaş U, Duygu H, Levent F, Şimşek EÇ, Yapan Emren Z, et al. The role of HATCH score in predicting the success rate of sinus rhythm following electrical cardioversion of atrial fibrillation. Kardiol Pol. 2016;74 (9):978–84. DOI: 10.5603/KP.a2016.0044.

Emren SV, Kocabaş U, Duygu H, Levent F, Şimşek EÇ, Yapan Emren Z, Tülüce S. The role of HATCH score in predicting the success rate of sinus rhythm following electrical cardioversion of atrial fibrillation. Kardiol Pol. 2016;74(9):978-84. doi: 10.5603/KP.a2016.0044. Epub 2016 Apr 4. PMID: 27040017.

Kochhäuser S, Dechering DG, Trought K, Hache P, haigcarter T, Khaykin Y, et al. Predictors for Progression of Atrial Fibrillation in Patients Awaiting Atrial Fibrillation Ablation. Can J Cardiol. 2016;32 (11):1348–1354. DOI: 10.1016/j.Cjca.2016.02.031.

Kochhäuser S, Dechering DG, Trought K, Hache P, Haig-Carter T, Khaykin Y, Wulffhart Z, Pantano A, Tsang B, Eckardt L, Verma A. Predictors for Progression of Atrial Fibrillation in Patients Awaiting Atrial Fibrillation Ablation. Can J Cardiol. 2016 Nov;32(11):1348-1354. doi: 10.1016/j.cjca.2016.02.031. Epub 2016 Feb 9. PMID: 27118059.

Pisters R, Nieuwlaat R, Prins MH, Le Heuzey JY, Maggioni AP, Camm AJ, et al. Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace. 2012;14 (5):666–74. DOI: 10.1093/europace/eur406.

Pisters R, Nieuwlaat R, Prins MH, Le Heuzey JY, Maggioni AP, Camm AJ, Crijns HJ; Euro Heart Survey Investigators. Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace. 2012 May;14(5):666-74. doi: 10.1093/europace/eur406. Epub 2012 Jan 5. PMID: 22223715.

Roh SY, Choi JI, Lee JY, Kwak JJ, Park JS, Kim JB, et al. Catheter ablation of atrial fibrillation in patients with chronic lung disease. Circ Arrhythm Electrophysiol. 2011;4 (6):815–22. DOI: 10.1161/CIRCEP.110.960435.

Roh SY, Choi JI, Lee JY, Kwak JJ, Park JS, Kim JB, Lim HE, Kim YH. Catheter ablation of atrial fibrillation in patients with chronic lung disease. Circ Arrhythm Electrophysiol. 2011 Dec;4(6):815-22. doi: 10.1161/CIRCEP.110.960435. Epub 2011 Sep 26. PMID: 21946388.

Gu J, Liu X, Tan H, Zhou L, Jiang W, Wang Y, et al. Impact of chronic obstructive pulmonary disease on procedural outcomes and quality of life in patients with atrial fibrillation undergoing catheter ablation. J Cardiovasc Electrophysiol. 2013;24 (2):148– 54. DOI: 10.1111/j.1540–8167.2012.02448.x.

Gu J, Liu X, Tan H, Zhou L, Jiang W, Wang Y, Liu Y, Gu J. Impact of chronic obstructive pulmonary disease on procedural outcomes and quality of life in patients with atrial fibrillation undergoing catheter ablation. J Cardiovasc Electrophysiol. 2013 Feb;24(2):148-54. doi: 10.1111/j.1540-8167.2012.02448.x. Epub 2012 Oct 15. PMID: 23066893.

Nadeem R, Sharieff A, Tanna S, Sidhu H, Molnar J, Nadeem A. Potential Augmentation of the Risk of Ischemic Cerebrovascular Accident by Chronic Obstructive Pulmonary Disease in Patients with Atrial Fibrillation. J Stroke Cerebrovasc Dis. 2015;24 (8):1893–6. DOI: 10.1016/j.jstrokecerebrovasdis.2015.04.034.

Nadeem R, Sharieff A, Tanna S, Sidhu H, Molnar J, Nadeem A. Potential Augmentation of the Risk of Ischemic Cerebrovascular Accident by Chronic Obstructive Pulmonary Disease in Patients with Atrial Fibrillation. J Stroke Cerebrovasc Dis. 2015 Aug;24(8):1893-6. doi: 10.1016/j.jstrokecerebrovasdis.2015.04.034. Epub 2015 Jun 30. PMID: 26142261.

Proietti M, Laroche C, Drozd M, Vijgen J, Cozma DC, Drozdz J, et al. Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the eurobservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. Am Heart J. 2016;181:83–91. DOI: 10.1016/j.ahj.2016.08.011.

Proietti M, Laroche C, Drozd M, Vijgen J, Cozma DC, Drozdz J, Maggioni AP, Boriani G, Lip GY; EORP-AF Investigators. Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. Am Heart J. 2016 Nov;181:83-91. doi: 10.1016/j.ahj.2016.08.011. Epub 2016 Aug 27. PMID: 27823697.

Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M, et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the eurobservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Europace. 2018;20 (5):747–757. DOI: 10.1093/europace/eux301.

Giuseppe Boriani, Marco Proietti, Cécile Laroche, Laurent Fauchier, Francisco Marin, Michael Nabauer, Tatjana Potpara, Gheorghe-Andrei Dan, Zbigniew Kalarus, Igor Diemberger, Luigi Tavazzi, Aldo P Maggioni, Gregory Y H Lip, the EORP-AF Long-Term General Registry Investigators, Steering Committee (National Coordinators), Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry, EP Europace, Volume 20, Issue 5, May 2018, Pages 747–757, https://doi.org/10.1093/europace/eux301.

Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M, et al. Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. Europace. 2019;21 (7):1013–1022. DOI: 10.1093/europace/euz032.

Giuseppe Boriani, Marco Proietti, Cécile Laroche, Laurent Fauchier, Francisco Marin, Michael Nabauer, Tatjana Potpara, Gheorghe-Andrei Dan, Zbigniew Kalarus, Luigi Tavazzi, Aldo P Maggioni, Gregory Y H Lip, EORP-AF Long-Term General Registry Investigators, Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry, EP Europace, Volume 21, Issue 7, July 2019, Pages 1013–1022, https://doi.org/10.1093/europace/euz032.

Huang B, Yang Y, Zhu J, Liang Y, Zhang H, Tian L, et al. Clinical characteristics and prognostic significance of chronic obstructive pulmonary disease in patients with atrial fibrillation: results from a multicenter atrial fibrillation registry study. J Am Med Dir Assoc. 2014;15 (8):576–81. DOI: 10.1016/j.Jamda.2014.04.009.

Huang B, Yang Y, Zhu J, Liang Y, Zhang H, Tian L, Shao X, Wang J. Clinical characteristics and prognostic significance of chronic obstructive pulmonary disease in patients with atrial fibrillation: results from a multicenter atrial fibrillation registry study. J Am Med Dir Assoc. 2014 Aug;15(8):576-81. doi: 10.1016/j.jamda.2014.04.009. Epub 2014 Jun 2. PMID: 24894999.

Ugowe FE, Hellkamp AS, Wang A, Becker RC, Berkowitz SD, Breithardt G, et al. Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF. Heart Rhythm O2. 2021;2 (3):215–222. DOI: 10.1016/j.hroo.2021.04.001.

Ugowe FE, Hellkamp AS, Wang A, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Singer DE, Patel MR, Piccini JP; of the ROCKET AF Steering Committee and Investigators. Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF. Heart Rhythm O2. 2021 Apr 20;2(3):215-222. doi: 10.1016/j.hroo.2021.04.001. PMID: 34337571; PMCID: PMC8322824.

Al-Khatib SM, Mulder H, Wojdyla D, Lopes RD, Wallentin L, Alexander JH, et al. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial. Circ Arrhythm Electrophysiol. 2021;14 (3): e009614. DOI: 10.1161/CIRCEP.120.009614.

Al-Khatib SM, Mulder H, Wojdyla D, Lopes RD, Wallentin L, Alexander JH, Hijazi Z, Goto S, Granger CB. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial. Circ Arrhythm Electrophysiol. 2021 Mar;14(3):e009614. doi: 10.1161/CIRCEP.120.009614. Epub 2021 Mar 4. PMID: 33657831.

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for cardiothoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42 (5):373–498. DOI: 10.1093/eurheartj/ehaa612. Erratum in: Eur Heart J. 2021;42 (5):507. Erratum in: Eur Heart J. 2021;42 (5):546–547. Erratum in: Eur Heart J. 2021. PMID: 32860505.

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612. Erratum in: Eur Heart J. 2021 Feb 1;42(5):507. Erratum in: Eur Heart J. 2021 Feb 1;42(5):546-547. Erratum in: Eur Heart J. 2021 Sep 14;: PMID: 32860505.

Gulea C, Zakeri R, Alderman V, Morgan A, Ross J, Quint JK. Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison. Respir Res. 2021;22 (1):64. DOI: 10.1186/s12931-021-01661-8.

Huang B, Yang Y. Radiofrequency catheter ablation of atrial fibrillation in patients with chronic obstructive pulmonary disease: opportunity and challenge: response to Dr. Kumar’s comment. J Am Med Dir Assoc. 2015;16 (1):83–4. DOI: 10.1016/j.jamda.2014.09.014.

Huang B, Yang Y. Radiofrequency catheter ablation of atrial fibrillation in patients with chronic obstructive pulmonary disease: opportunity and challenge: response to Dr. Kumar's comment. J Am Med Dir Assoc. 2015 Jan;16(1):83-4. doi: 10.1016/j.jamda.2014.09.014. Epub 2014 Oct 25. PMID: 25444574.

The authors declare that there are no conflicts of interest present.